Carlos A Zarate Selected Research

N-Methylaspartate (NMDA)

1/2022	Transcriptional Activation, Deactivation and Rebound Patterns in Cortex, Hippocampus and Amygdala in Response to Ketamine Infusion in Rats.
1/2018	Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
2/2017	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.
2/2015	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression.
10/2014	Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
3/2014	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
1/2014	Biomarkers in mood disorders research: developing new and improved therapeutics.
1/2014	Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
9/2013	Ketamine, sleep, and depression: current status and new questions.
6/2013	Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos A Zarate Research Topics

Disease

94	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 01/2002
85	Major Depressive Disorder (Major Depressive Disorders) 07/2022 - 01/2006
47	Mood Disorders (Mood Disorder) 01/2022 - 01/2002
33	Treatment-Resistant Depressive Disorder 01/2022 - 04/2003
19	Mania (Manias) 01/2022 - 01/2002
7	Substance-Related Disorders (Drug Abuse) 10/2022 - 08/2003
6	Alcoholism (Alcohol Abuse) 01/2017 - 12/2006
5	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022 - 03/2011
5	Mental Disorders (Mental Disorder) 01/2021 - 01/2014
4	Inflammation (Inflammations) 01/2022 - 01/2010
4	Fatigue 01/2022 - 01/2013
4	Anhedonia 01/2019 - 05/2015
4	Psychotic Disorders (Schizoaffective Disorder) 01/2017 - 06/2009
4	Depressive Disorder (Melancholia) 01/2015 - 07/2004
4	Sleep Deprivation 06/2013 - 11/2002
4	Weight Gain 11/2006 - 01/2002
3	Anxiety Disorders (Anxiety Disorder) 03/2016 - 12/2006
3	Sleepiness 07/2003 - 01/2002
2	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022 - 05/2014
2	Pain (Aches) 01/2022 - 01/2022
2	Neuroinflammatory Diseases 01/2021 - 07/2018
2	Chronic Pain 01/2021 - 01/2020
2	Syndrome (Syndromes) 05/2018 - 03/2011
2	B-Cell Lymphoma (Lymphoma, B Cell) 02/2011 - 01/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2010 - 06/2009
2	Nausea 07/2003 - 06/2002
1	Social Phobia 01/2022
1	Confusion (Bewilderment) 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Complex Regional Pain Syndromes 01/2022
1	Neuralgia (Stump Neuralgia) 01/2022

Drug/Important Bio-Agent (IBA)

93	Ketamine FDA LinkGeneric 10/2022 - 12/2007
84	Antidepressive Agents (Antidepressants)IBA 07/2022 - 11/2002
27	LithiumIBA 01/2022 - 01/2002
23	Pharmaceutical PreparationsIBA 01/2020 - 08/2003
22	N-Methylaspartate (NMDA)IBA 01/2022 - 04/2003
17	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 01/2009
15	Valproic Acid (Depakote)FDA LinkGeneric 01/2017 - 01/2002
14	Glutamic Acid (Glutamate)FDA Link 01/2019 - 11/2003
13	EsketamineIBA 01/2022 - 11/2014
13	Biomarkers (Surrogate Marker)IBA 01/2020 - 02/2009
8	Scopolamine (Hyoscine)FDA Link 01/2019 - 03/2012
8	Riluzole FDA LinkGeneric 06/2017 - 04/2004
7	Olanzapine (Zyprexa)FDA Link 07/2010 - 01/2002
6	Antipsychotic Agents (Antipsychotics)IBA 12/2012 - 06/2003
5	Proteins (Proteins, Gene)FDA Link 10/2022 - 06/2009
5	Glutamate Receptors (Glutamate Receptor)IBA 01/2021 - 10/2013
5	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2018 - 04/2003
5	Biological ProductsIBA 11/2016 - 02/2011
5	Serotonin (5 Hydroxytryptamine)IBA 08/2014 - 11/2010
5	EnzymesIBA 05/2014 - 01/2004
4	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2015 - 11/2010
4	Neurotransmitter Agents (Neurotransmitter)IBA 08/2014 - 01/2008
4	Protein Kinase CIBA 01/2010 - 09/2007
3	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2020 - 02/2017
3	GlucocorticoidsIBA 02/2017 - 11/2010
3	Anesthetics (Anesthetic Agents)IBA 01/2017 - 10/2012
3	Glucose (Dextrose)FDA LinkGeneric 05/2015 - 03/2014
3	Sertraline (Zoloft)FDA LinkGeneric 01/2015 - 04/2014
3	Dopamine (Intropin)FDA LinkGeneric 08/2014 - 11/2010
3	CalciumIBA 02/2014 - 02/2011
3	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2014 - 11/2010
3	Pramipexole (Mirapex)FDA LinkGeneric 07/2013 - 07/2004
3	Dopamine Agonists (Dopamine Agonist)IBA 07/2013 - 11/2010
3	Nerve Growth Factors (Neurotrophins)IBA 01/2010 - 06/2009
3	Glycogen Synthase Kinase 3IBA 01/2010 - 01/2004
3	Tamoxifen FDA LinkGeneric 01/2009 - 09/2007
3	Anticonvulsants (Antiepileptic Drugs)IBA 09/2008 - 12/2006
3	Lamotrigine (Lamictal)FDA LinkGeneric 04/2007 - 02/2004
3	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 12/2006 - 04/2003
2	6-hydroxynorketamineIBA 10/2022 - 01/2019
2	Opioid Analgesics (Opioids)IBA 07/2022 - 01/2014
2	norketamineIBA 01/2022 - 08/2012
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2019 - 02/2017
2	Muscarinic AntagonistsIBA 01/2019 - 08/2016
2	propionic acid (potassium propionate)IBA 01/2018 - 06/2006
2	Cholinergic Agents (Cholinergics)IBA 02/2017 - 06/2013
2	CytokinesIBA 01/2017 - 02/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2016 - 08/2011
2	salicylhydroxamic acid (SHAM)IBA 07/2014 - 04/2014
2	AntioxidantsIBA 03/2014 - 01/2012
2	RolipramIBA 01/2014 - 11/2012
2	Amino Acids FDA Link 10/2013 - 09/2012
2	5-HT1A Serotonin ReceptorIBA 10/2013 - 08/2013
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 03/2013 - 01/2010
2	Therapeutic UsesIBA 10/2012 - 01/2009
2	Excitatory Amino Acid AgentsIBA 02/2012 - 05/2008
2	Adenosine Monophosphate (AMP)IBA 01/2010 - 06/2006
2	Antimanic AgentsIBA 12/2008 - 09/2007
2	3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)IBA 12/2006 - 04/2003
1	LipidsIBA 01/2022
1	mesoglycanIBA 01/2022
1	EndocannabinoidsIBA 01/2022
1	KynurenineIBA 01/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	ProdrugsIBA 01/2020

Therapy/Procedure

36	Therapeutics 01/2022 - 01/2002
6	Drug Therapy (Chemotherapy) 01/2017 - 06/2006
3	Intravenous Infusions 01/2019 - 10/2012
3	Transcranial Direct Current Stimulation 01/2015 - 04/2014